Neu Health Joins Global Incubator for U.S. Expansion in Neurology
Neu Health has been selected for the Global Incubator Programme (GIP): USA HealthTech - Medical Devices, announced in a press release. This six-month program, delivered by Innovate UK in partnership with Texas Medical Center Innovation (TMCi), aims to support UK medical device and digital health companies entering the U.S. market.
The program provides access to Houston's Texas Medical Center, the world's largest medical complex, which treats 10 million patients annually. This selection follows Neu Health's recent U.S. launch and FDA 510(k) clearance for its smartphone-based tool for measuring resting tremor in Parkinson's disease. The tool is the first fully phone-based system for measuring motor symptoms without wearable or in-clinic hardware.
Neu Health is already piloting its platform at Cedars-Sinai and Mass General Brigham, with further U.S. expansions planned. The GIP will enable Neu Health to connect with clinical leaders and investor networks, facilitating partnerships and growth opportunities in the U.S. market. The program runs from September 2025 to March 2026, combining virtual incubation with on-site immersion in Houston.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Helfie AI and Health Innovation South West to Test Smartphone Hypertension Screening
Zus Health raises $33 million to build the data layer for healthcare AI
INmune Bio and QCi Apply Quantum Computing to XPro Research
Neura Robotics Launches Neuron AI for Humanoid Robots
Healthcare Triangle Identifies Up to $45 Million Indonesia Pipeline
Daily AI Brief: the AI news that matters, in your inbox.